xRead - Olfactory Disorders (September 2023)

20426984, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22929, Wiley Online Library on [04/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

555

PATEL et al.

TABLE IX-4 (Continued)

Clinical end point

Study Small

Year 2005

LOE Study design Study groups

Conclusions Compared with

Subjective

2

RCT

CRSwNP (N = 354) MFNS200 μ g once daily (n = 115) MFNS200 μ g twice daily (n = 122) Placebo (n = 117)

et al 1397

placebo, both MF groups demonstrated significantly greater improvement in subjective symptom score at week 4 and week 12 preoperative values, there was significant improvement in VAS in all groups placebo, there was no significant benefit in either FP groups placebo, there was no significant benefit in subjective symptom score in the FP group

symptom score (0–3)

Data collection:

week 4, week 12

Djikstra

2004

2

RCT

CRS (n = 162) Underwent ESS followed by: FPNS400 μ g twice daily × 1 year (n = 53) FPNS800 μ g twice daily × 1 year (n = 53) Placebo twice daily × 1 year (n = 56)

VAS (0–100)

Compared with

et al 1398

Compared with

Parikh

Compared with

Subjective

2001

2

RCT

CRS (N = 22) FPNS (n = 9) Placebo (13)

et al 1399

symptom score (0–3)

Janowski et al 1400

2001

2

RCT(4

CRSwNP (N = 183) Budesonide NS 128 μ g once daily am + Budesonide NS 128 μ g twice daily × 8weeks Budesonide NS 256 μ g once daily am + placebopm Placebo × 8weeks placebopm × 8weeks

Subjective

Compared with placebo, all budesonide

budesonide groups vs placebo for 8 weeks)

symptom score (0–4)

Data collection: daily diary

treatment groups demonstrated significantly greater improvement in subjective symptom scores

symptom cards

Effect on symptoms became apparent within 1 to 2 days

Keith

Subjective

Compared with

2000

2

RCT

CRSwNP (N = 104) Nasal FP drops 400 μ g once daily (n = 52) Placebo (n = 52)

et al 1401

symptom score (0–3)

placebo, FP drops did not demonstrate significant benefit in any of the olfactory outcome measures

UPSIT R BTS Data collection: week 12

Penttilä

2000

2

RCT

CRSwNP (N = 142) FPNS400 μ g twice daily (n = 47) FPNS400 μ g once daily (n = 47) Placebo (n = 47)

UPSIT R BTS Subjective

Compared with

et al 1402

placebo, patients with twice-daily dosing demonstrated statistically significant improvement in

symptom score (0–3)

Data collection points: week 4, week 8, week 12

UPSIT R at one time point (not specified when) (Continues)